The John Ultmann lecture - The role of radiation therapy in the treatment of Hodgkin's disease: Past, present, and future

European Journal of Haematology, Supplement

Volumn 75, Issue 66, 2005, Pages 14-20

  Hoppe, Richard T ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Combined modality therapy; History; Hodgkin's disease; Radiation therapy; Ultmann

Indexed keywords

BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; HODGKIN DISEASE; HUMAN; MULTIMODALITY CANCER THERAPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; EDITORIAL; HISTORY; RADIOTHERAPY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HODGKIN DISEASE; HUMANS; RADIOTHERAPY;

EID: 21044451883     PISSN: 09024506     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2005.00449.x     Document Type: Conference Paper

References (31)

1. PUSEY WE. Cases of Sarcoma and of Hodgkin's disease treated by exposures to X-rays - a preliminary report. JAMA 1902;38:166-169.
2. PUSEY WA, CALDWELL EW. The Practical Application of the Roentgen Rays in Therapeutics and Diagnosis. Philadelphia: W. B. Saunders & Co. 1904.
3. GILBERT R, BABAIANTZ L. Notre methode de roentgentherapie de la lymphogranulomatose (Hodgkin): resultats eloignes. Acta Radiol 1931;12:523-529.
4. PETERS V. A study of Hodgkin's disease treated radiologically. Am J Roentgenol 1950;63:299-311.
5. KAPLAN HS. The radical radiotherapy of regionally localized Hodgkin's disease. Radiology 1962;78:553-561.
6. ROSENBERG SA, KAPLAN HS. The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin's disease: 1962-1984. Int J Radiat Oncol Biol Phys 1985;11:5-22.
7. BONADONNA G, BONFANTE V, VIVIANI S, DI RUSSO A, VILLANI F, VALAGUSSA P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 2004; 22:2835-2841.
8. ENGERT A, SCHILLER P, JOSTING A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003;21:3601-3608.
9. RAEMAEKERS J. EUR J Cancer Clin Oncol 2002;38:S107-S113.
10. HORNING S, HOPPE R, BRESLIN S, BAER D, MASON SA, ROSENBERG S. Very brief (8 week) chemotherapy (CT) and low dose (30 Gy) radiotherapy (RT) for limited stage Hodgkin's disease (HD): preliminary results of the Stanford-Kaiser G4 study of Stanford V + RT. ASH 2000, abstract 1717.
11. DIEHL V, THOMAS RK, RE D. Part II: Hodgkin's lymphoma-diagnosis and treatment. Lancet Oncol 2004; 5:19-26.
12. DIEHL V. Chemotherapy or combined modality treatment: the optimal treatment for Hodgkin's disease. J Clin Oncol 2004;22:15-18.
13. NOORDIJK EM, THOMAS J, FERME C, VAN'T VEER MB, BRICE P, DIVINE M, MORSCHHAUSER F, CARDE P, EGHBALI H, HENRY-AMAR M. First results of the EORTC-GELA H9 randomized trials: the H9F trial (comparing 3 radiation dose levels) and H9U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (abstr.) ASCO 2005, abstract #30245.
14. MEYER R. A randomized Phase III comparison of single-modality. Blood 2003;102.
15. HOPPE RT, COLEMAN CN, COX RS, ROSENBERG SA, KAPLAN HS. The management of stage I-II Hodgkin's disease with irradiation alone or combined modality therapy: the Stanford experience. Blood 1982;59:455-465.
16. LONGO DL, RUSSO A, DUFFEY PL, HUBBARD SM, GLATSTEIN E, HILL JB, JAFFE ES, YOUNG RC, DE VITA VT Jr. Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment. J Clin Oncol 1991;9:227-235.
17. HORNING SJ, HOPPE RT, ADVANI R, WARNKE R, BAER D, MASON J, ROSENBERG SA. Efficacy and late effects of Stanford V chemotherapy and radiotherapy in untreated Hodgkin's disease: mature data in early and advanced stage patients. (abstr.) ASH 2004 Abstract #308.
18. DIEHL V, FRANKLIN J, SEXTRO M, MAUCH P. Clinical presentation and treatment of lymphocyte predominance Hodgkin's disease. In: MAUCH P, ARMITAGE JO, DIEHL V, HOPPE R, WEISS LM, eds. Hodgkin's Disease. Philadelphia: Lippincott Williams & Wilkins, 1999:563-584.
19. WIRTH A, CHAD M, CORRY J, et al. Mantle irradiation alone for clinical stage I-II Hodgkin's disease: long-term follow-up and analysis of prognostic factors in 261 patients. J Clin Oncol 1999;17:230-240.
20. NCCN Treatment Guidelines for Hodgkin's Disease Therapy. http://www.nccn.org
21. ALEMAN BM, RAEMAEKERS JM, TIRELLI U et al. Involved field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 2003;348:2396-2406.
22. CHISESI T, FEDERICO M, LEVIS A, DELILIERS GL, GOBBI PG, SANTINI G, LUMINARI S, LINFOMI MB, INTERGRUPPO ITALIANO L. ABVD versus Stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial. Ann Oncol 2002;13(Suppl 1):102-106.
23. MOSKOWITZ CH, KEWALRAMANI T, NIMER SD, GONZALEZ M, ZELENETZ AD, YAHALOM J. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 2004;124: 645-652.
24. POEN JC, HOPPE RT, HORNING SJ. High-dose therapy and autologous bone marrow transplantation for relapsed/ refractory Hodgkin's disease: the impact of involved field radiotherapy on patterns of failure and survival [see comments]. Int J Radiat Oncol Biol Phys 1996;36:3-12.
25. BEHRINGER K, JOSTING A, SCHILLER P, EICH HT, BREDENFELD H, DIEHL V, ENGERT A. Solid tumors in patients treated for Hodgkin's disease: a report from the German Hodgkin Lymphoma Study Group. Ann Oncol 2004; 15:1079-1085.
26. VAN LEEUWEN FE, KLOKMAN WJ, STOVALL M, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease [see comment]. J Natl Cancer Inst 2003;95:971-980.
27. GILBERT ES, STOVALL M, GOSPODAROWICZ M, et al. Lung cancer after treatment for Hodgkin's disease: focus on radiation effects. Radiat Res 2003;159:161-173.
28. HANCOCK SL, TUCKER MA, HOPPE RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 1993;270:1949-1955.
29. HANCOCK SL, DONALDSON SS, HOPPE RT. Cardiac disease following treatment of Hodgkin's disease in children and adolescents [see comments]. J Clin Oncol 1993;11:1208-1215.
30. DUHMKE E, FRANKLIN J, PFREUNDSCHUH M, et al. Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol 2001;19:2905-2914.
31. EICH HT, STAAR S, GOSSMANN A, et al. Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys 2004;58:1121-1127.